COMBINATIONS OF AMBRISENTAN AND PDE5 INHIBITORS FOR TREATING PULMONARY ARTERIAL HYPERTENSION

摘要

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (PAH) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years.